Entvin AI, a regulatory intelligence startup focused on the pharmaceutical and life sciences sectors, has officially launched from beta and secured $500,000 in seed funding from Y Combinator. The company, founded in 2022 by Sanskar Jain, Hemant Phalak, and Rishabh Arya, is using artificial intelligence to simplify and accelerate the FDA drug approval process.
Entvin’s platform leverages fine-tuned large language models to automate critical regulatory workflows, including document drafting, compliance checks, and real-time monitoring. The company said inefficiencies in FDA submissions delay life-saving treatments and cost firms millions. Early enterprise pilots have shown that Entvin’s tools can save regulatory teams hundreds of hours while increasing accuracy and reducing risks.
